Ponatinib

Name Value
Weight 532.570 g/mol
Zinc ID ZINC36701290
Smiles Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Molecular formula C29H27F3N6O
Mode of inhibition VEGF, FGFR, PDGFR, STAT; Tyrosine kinase inhibitor
CAS 943319-70-8

Clinical Trials

Study title Status Conditions Link
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) Recruiting Chronic Myeloid Leukemia, Chronic Phase NCT04160546
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors Recruiting Acute Myeloid Leukemia|Accelerated Phase Chronic Myeloid Leukemia|Blast Phase Chronic Myeloid Leukemia|Chronic Phase Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphocytic Leukemia|Leukemia|Lymphoma|Solid Tumors NCT03934372
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer Not yet recruiting Medullary Thyroid Cancer NCT03838692
Ponatinib for FLT3-ITD Acute Myelogenous Leukemia Recruiting Acute Myeloid Lukemia NCT02428543
A Study in Patients With Chronic Leukemia, Where Previous Therapy Failed, and Who Will be Treated With Ponatinib as Second Line Therapy (PONS). Recruiting Leukemia, Myeloid, Chronic-Phase NCT03807479
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia Recruiting Chronic Myeloid Leukemia NCT04043676
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase Active, not recruiting Philadelphia Chromosome Positive CML|BCR-ABL Positive Chronic Myelogenous Leukemia NCT04070443
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma Withdrawn Endometrial Neoplasms NCT01888562
Ponatinib for Squamous Cell Lung and Head and Neck Cancers Terminated Non-Small Cell Lung Cancer, Head and Neck Cancer NCT01761747
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Terminated Leukemia NCT01570868
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Active, not recruiting Adenocarcinoma of the Lung|Extensive Stage Small Cell Lung Cancer|Limited Stage Small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer NCT01935336
Expanded Access Program of Ponatinib Approved for marketing Chronic Myeloid Leukemia (CML)|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) NCT01592136
A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Active, not recruiting Chronic Phase Chronic Myeloid Leukemia NCT02627677
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma Completed Glioblastoma NCT02478164
Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients Recruiting Leukemia, Myeloid, Acute NCT03690115
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed GIST NCT01874665
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Withdrawn Leukemia|FLT3-Mutated Acute Myeloid Leukemia|FLT3-Mutated High-Risk Myelodysplastic Syndrome NCT02829840
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib Recruiting Chronic Myeloid Leukemia|Chronic Phase|Adults NCT02398825
A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Completed Chronic Myeloid Leukemia (CML)|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) NCT01667133
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Recruiting Malignant Neoplasm NCT02272998
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Completed Chronic Myeloid Leukemia|Ph+ Acute Lymphoblastic Leukemia NCT01207440
POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST Recruiting GIST, Malignant|KIT Exon 13 Mutation|KIT Gene Mutation NCT03171389
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation Not yet recruiting Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia NCT04233346
An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL Recruiting Lymphoblastic Leukemia, Acute, Adult|Acute Lymphoid Leukemia|Leukemia, Acute Lymphoblastic|Leukemia, Lymphoblastic|Ph1 Chromosome|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive NCT03589326
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I Completed Leukemia NCT02981784
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia Not yet recruiting Acute Myeloid Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive NCT04188405
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions Completed Malignant Hepatobiliary Neoplasm NCT02265341
Compassionate Use Ponatinib No longer available Philadelphia Chromosome Positive (Ph+) Leukemias|Chronic Myeloid Leukemia NCT01549548
Ponatinib in Advanced NSCLC w/ RET Translocations Completed Non Small Cell Lung Cancer NCT01813734
Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. Active, not recruiting Philadelphia Positive|BCR-ABL Positive|Acute Lymphoblastic Leukemia NCT01641107
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses Active, not recruiting Myeloid Leukemia, Chronic, Chronic Phase NCT02467270
Iclusig PMS in CML or Ph+ALL Patients Recruiting Chronic Myeloid Leukemia|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia NCT03709017
Ponatinib for Advanced Medullary Thyroid Cancer Terminated Thyroid Neoplasms NCT01838642
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib Active, not recruiting Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive NCT01746836
PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS Recruiting CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS NCT03895671
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies Completed Chronic Myelogenous Leukemia|Hematologic Malignancies NCT00660920
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) Terminated Chronic Myeloid Leukemia NCT01650805
Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia Recruiting ALL NCT02776605
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium Recruiting Chronic Myeloid Leukemia|CML|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Ph+ ALL NCT03678454
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Recruiting Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|t(9 NCT03576547
Vascular Cardiotoxicity of Ponatinib Recruiting Cardiotoxicity NCT03930394
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Recruiting Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia|t(9 NCT03263572
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Recruiting Non Small Cell Lung Cancer|KRAS Gene Mutation NCT03704688
A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON" Withdrawn BCR-ABL Positive Acute Lymphoblastic Leukemia NCT03515785
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) Recruiting Chronic Myeloid Leukemia NCT04048564
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia Recruiting Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia With BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia NCT03147612
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Recruiting Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(9 NCT01424982
Retrospective Evaluation of CML Patients in the National Compassionate Program Recruiting Chronic Myeloid Leukemia|Philadelphia Positive NCT02448095
Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose Recruiting Chronic Myeloid Leukemia, Chronic Phase NCT03933852
An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® Recruiting Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL NCT02455024
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Recruiting Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia NCT01620216
A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia Recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia NCT03878524
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia NCT02779283
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality Recruiting Chronic Myeloid Leukemia (CML) NCT03746054
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) Recruiting Leukemia, Myeloid, Chronic-Phase NCT02767063
Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. Recruiting Chronic Myeloid Leukemia|Tyrosine Kinase Inhibitor|Withdrawal Syndrome NCT03996096
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia Unknown status Leukemia, Lymphoblastic, Acute NCT03331211
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants Recruiting Philadelphia Chromosome Positive Acute Lymphocytic Leukemia|Tyrosine Kinase Inhibitor|Minimal Residual Disease|Allogeneic Hematopoietic Stem Cell Transplantation NCT03624530
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Unknown status Philadelphia Chromosome Positive Acute Lymphocytic Leukemia|Stem Cell Transplantation|Minimal Residual Disease NCT01883219
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey Recruiting Chronic Phase Chronic Myelogenous Leukemia|Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia NCT03647215
Study of HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia Recruiting Leukemia, Myeloid, Chronic|Myeloid Leukemia|Chronic Myeloid Leukemia NCT04260022
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Recruiting Acute Leukemia of Ambiguous Lineage|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia NCT02551718

References

Publication DOI Pubmed PMCID
Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers Fiona H Tan, Tracy L Putoczki, Jieqiong Lou, Elizabeth Hinde, Frédéric Hollande, Julie Giraud, Stanley S Stylli, Lucia Paradiso, Hong-Jian Zhu, Oliver M Sieber, Rodney B Luwor, 10, 12, 2018-12-19, 2018-12-19, 10.3390/cancers10120526 10.3390/cancers10120526 30572654 PMC6316865
A comparison of the response to secretin, pancreozymin and a combination of these hormones, in man. Scandinavian journal of gastroenterology K G Wormsley, 4, 5, None, None, 10.18632/oncotarget.11580 10.18632/oncotarget.11580 5351597 PMC5351597

Vendors

Company Lnk to product
Selleckchem https://www.selleckchem.com/products/AP24534.html
Caymanchemical https://www.caymanchem.com/product/11494/ponatinib
BLDpharm https://www.bldpharm.com/products/943319-70-8.html
Adooq Bioscience https://www.adooq.com/ap24534-ponatinib.html

Filter data

Compound Ponatinib
Experiment types Cell Titer Glo assay, Colony formation assay , Fluorescent staining, Immunohistochemistry, Luciferase activity, Microscopic observation , RT-qPCR, Tumor size , Tumor volume, Tumor weight, WST-8, Western Blot, Wound healing assay
Concentrations 0.01, 0.05, 0.10, 0.50, 1.00, 10.00, 15.00, 2.00, 20.00, 30.00, 5.00
Cell lines C70, CACO2, CCK81, COLO205, COLO320, CPP14, CPP19, CPP35, DIFI, DLD-1, DLD-1 (xenograft), GEO, HCA-7, HI55, HT115, IMR-32, KM12, LA-N6, LIM1215, LIM2099, LIM2405, LIM2537, LOVO, NB-19, NB-19 (xenograft), NGP, SH-SY5Y, SK-N-AS, SNU175, SW48, SW48 (xenograft), SW620
Organisms Homo sapiens, Mus musculus
Animal models BALB/c, NCr nude mice
STAT proteins STAT3, p-STAT3, p-STAT3 (Y705)
Other AKT, Caspase-3, Cleaved Caspase-3, Cleaved PARP, GAPDH, JAK2, PARP, S6, SOCS3, p-AKT (S473), p-JAK2, p-S6 (Ser235/236), β-actin

Experiments

Compound Experiment type Investigated event Concentration Cell line Organism Animal model Stat protein Details
Ponatinib Luciferase activity Influence on protein activity in presence of IL-6 10.00 µM DLD-1 Homo sapiens
Ponatinib Luciferase activity Influence on protein activity in presence of EGF 10.00 µM DIFI Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM DIFI Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM DIFI Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM DIFI Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM DIFI Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM DIFI Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM DIFI Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM DIFI Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM DIFI Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM DIFI Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM DLD-1 Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM DLD-1 Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM DLD-1 Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM DLD-1 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM DLD-1 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM DLD-1 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM DLD-1 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM DLD-1 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM DLD-1 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM SW48 Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM SW48 Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM SW48 Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM SW48 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM SW48 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM SW48 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.01 µM SW48 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 0.10 µM SW48 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM SW48 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-6 1.00 µM DLD-1 Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-6 10.00 µM DLD-1 Homo sapiens p-STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-6 1.00 µM DLD-1 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-6 10.00 µM DLD-1 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of IL-6 1.00 µM DLD-1 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-6 10.00 µM DLD-1 Homo sapiens
Ponatinib Fluorescent staining Influence on protein translocation in presence of IL-11 0.10 µM DLD-1 Homo sapiens STAT3
Ponatinib Fluorescent staining Influence on protein translocation in presence of IL-11 1.00 µM DLD-1 Homo sapiens STAT3
Ponatinib RT-qPCR Influence on gene expression 0.10 µM DIFI Homo sapiens
Ponatinib RT-qPCR Influence on gene expression 0.50 µM DIFI Homo sapiens
Ponatinib RT-qPCR Influence on gene expression 1.00 µM DIFI Homo sapiens
Ponatinib RT-qPCR Influence on gene expression 0.10 µM DLD-1 Homo sapiens
Ponatinib RT-qPCR Influence on gene expression 0.50 µM DLD-1 Homo sapiens
Ponatinib RT-qPCR Influence on gene expression 1.00 µM DLD-1 Homo sapiens
Ponatinib RT-qPCR Influence on gene expression 0.10 µM SW48 Homo sapiens
Ponatinib RT-qPCR Influence on gene expression 0.50 µM SW48 Homo sapiens
Ponatinib RT-qPCR Influence on gene expression 1.00 µM SW48 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM DLD-1 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of IL-11 1.00 µM DLD-1 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM DIFI Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM DLD-1 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM SW48 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM CPP14 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM CPP19 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM CPP35 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM CACO2 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM LIM1215 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM LOVO Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM HI55 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM LIM2099 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM LIM2405 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM HT115 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM GEO Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM COLO320 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM LIM2537 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM HCA-7 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM COLO205 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM KM12 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM CCK81 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM SW620 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM SNU175 Homo sapiens
Ponatinib Cell Titer Glo assay Influence on cell proliferation 1.00 µM C70 Homo sapiens
Ponatinib Wound healing assay Influence on cell migration 1.00 µM DLD-1 Homo sapiens
Ponatinib Wound healing assay Influence on cell migration 0.10 µM DLD-1 Homo sapiens
Ponatinib Wound healing assay Influence on cell migration 0.50 µM DLD-1 Homo sapiens
Ponatinib Wound healing assay Influence on cell migration 1.00 µM SW48 Homo sapiens
Ponatinib Wound healing assay Influence on cell migration 0.10 µM SW48 Homo sapiens
Ponatinib Wound healing assay Influence on cell migration 0.50 µM SW48 Homo sapiens
Ponatinib Tumor volume Influence on tumor growth 10.00 mg/kg DLD-1 (xenograft) Mus musculus BALB/c
Ponatinib Tumor volume Influence on tumor growth 30.00 mg/kg DLD-1 (xenograft) Mus musculus BALB/c
Ponatinib Tumor volume Influence on tumor growth 10.00 mg/kg SW48 (xenograft) Mus musculus BALB/c
Ponatinib Tumor volume Influence on tumor growth 30.00 mg/kg SW48 (xenograft) Mus musculus BALB/c
Ponatinib Tumor weight Influence on tumor growth 10.00 mg/kg DLD-1 (xenograft) Mus musculus BALB/c
Ponatinib Tumor weight Influence on tumor growth 30.00 mg/kg DLD-1 (xenograft) Mus musculus BALB/c
Ponatinib Tumor weight Influence on tumor growth 10.00 mg/kg SW48 (xenograft) Mus musculus BALB/c
Ponatinib Tumor weight Influence on tumor growth 30.00 mg/kg SW48 (xenograft) Mus musculus BALB/c
Ponatinib Immunohistochemistry Influence on protein activity in tumor tissue 10.00 mg/kg DLD-1 (xenograft) Mus musculus BALB/c p-STAT3
Ponatinib Immunohistochemistry Influence on protein activity in tumor tissue 30.00 mg/kg DLD-1 (xenograft) Mus musculus BALB/c p-STAT3
Ponatinib Immunohistochemistry Influence on protein activity in tumor tissue 10.00 mg/kg SW48 (xenograft) Mus musculus BALB/c p-STAT3
Ponatinib Immunohistochemistry Influence on protein activity in tumor tissue 30.00 mg/kg SW48 (xenograft) Mus musculus BALB/c p-STAT3
Ponatinib WST-8 Influence on cell proliferation 0.05 µM IMR-32 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.50 µM IMR-32 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 1.00 µM IMR-32 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 5.00 µM IMR-32 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 10.00 µM IMR-32 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 20.00 µM IMR-32 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.05 µM NGP Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.50 µM NGP Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 1.00 µM NGP Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 5.00 µM NGP Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 10.00 µM NGP Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 20.00 µM NGP Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.05 µM NB-19 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.50 µM NB-19 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 1.00 µM NB-19 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 5.00 µM NB-19 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 10.00 µM NB-19 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 20.00 µM NB-19 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.05 µM SK-N-AS Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.50 µM SK-N-AS Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 1.00 µM SK-N-AS Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 5.00 µM SK-N-AS Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 10.00 µM SK-N-AS Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 20.00 µM SK-N-AS Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.05 µM SH-SY5Y Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.50 µM SH-SY5Y Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 1.00 µM SH-SY5Y Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 5.00 µM SH-SY5Y Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 10.00 µM SH-SY5Y Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 20.00 µM SH-SY5Y Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.05 µM LA-N6 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 0.50 µM LA-N6 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 1.00 µM LA-N6 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 5.00 µM LA-N6 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 10.00 µM LA-N6 Homo sapiens
Ponatinib WST-8 Influence on cell proliferation 20.00 µM LA-N6 Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 0.50 µM IMR-32 Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 5.00 µM IMR-32 Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 0.50 µM NGP Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 5.00 µM NGP Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 0.50 µM SK-N-AS Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 5.00 µM SK-N-AS Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 0.50 µM SH-SY5Y Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 5.00 µM SH-SY5Y Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 0.50 µM LA-N6 Homo sapiens
Ponatinib Microscopic observation Influence on cell morphology 5.00 µM LA-N6 Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 1.00 µM IMR-32 Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 5.00 µM IMR-32 Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 1.00 µM NGP Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 5.00 µM NGP Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 1.00 µM SK-N-AS Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 5.00 µM SK-N-AS Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 1.00 µM SH-SY5Y Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 5.00 µM SH-SY5Y Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 1.00 µM LA-N6 Homo sapiens
Ponatinib Colony formation assay Influence on cell growth 5.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity 10.00 µM IMR-32 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity 10.00 µM NB-19 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity 10.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity 10.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM NGP Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM NGP Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM NGP Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM NGP Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM NGP Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM NGP Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM NGP Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM NGP Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM SH-SY5Y Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM SH-SY5Y Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM SH-SY5Y Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM SH-SY5Y Homo sapiens p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM SH-SY5Y Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM SH-SY5Y Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM SH-SY5Y Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM SH-SY5Y Homo sapiens STAT3
Ponatinib Western Blot Influence on protein activity in presence of bFGF 2.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 5.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 10.00 µM SH-SY5Y Homo sapiens
Ponatinib Western Blot Influence on protein activity in presence of bFGF 20.00 µM SH-SY5Y Homo sapiens
Ponatinib WST-8 Influence on cell proliferation in presence of Dox 1.00 µM NGP Homo sapiens
Ponatinib WST-8 Influence on cell proliferation in presence of Dox 1.00 µM SK-N-AS Homo sapiens
Ponatinib WST-8 Influence on cell proliferation in presence of Dox 1.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM NGP Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM SK-N-AS Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM LA-N6 Homo sapiens
Ponatinib Western Blot Influence on apoptotic protein activity in presence of Dox 1.00 µM LA-N6 Homo sapiens
Ponatinib Tumor size Influence on tumor growth 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Tumor weight Influence on tumor growth 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice p-STAT3 (Y705)
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice STAT3
Ponatinib Western Blot Influence on protein activity in tumor tissue 15.00 mg/kg NB-19 (xenograft) Mus musculus NCr nude mice